RE-LY-trial-publication-10-year-anniversary
Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Search
Living with type 2 diabetes
People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.
PRRS Research Award 2022
Bridging science and veterinary practice for swine health: The winners of the European PRRS Award 2022
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.
Questions and Answers
Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.
Behind the Lab
Delve behind the lab to see how our Retinal Health scientists are spearheading research into novel therapeutics to treat retinopathies.
Meet the Partnering Team Video 2023
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Gerhard Kraus, Global Head of IT Infrastructure
Gerhard Kraus, Global Head of IT Infrastructure "Improving the health of humans and animals is our vision. What we do can make a huge impact"
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
GastroGard the first imported equine drug in China
GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
Mental Health
Human Pharma Clinical Pipeline Mental Health therapeutic area
Global Top Employer 2023
Global Top Employer 2023
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
vet scholars symposium
Veterinary students and researchers from 38 veterinary schools in North America and Europe gathered at the NIH in August to discuss the future of veterinary medicine.
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Transboundary animal diseases and veterinary preparedness
What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.
The status of schizophrenia care
A closer look at the status of the schizophrenia care landscape, an often misunderstood mental health condition